Carrara

Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.

This research aims to gather a large group of patients suspected of having coronary artery disease CAD who underwent Computed Tomography Coronary Angiography CTCA to better understand how CTCA helps in identifying the presence and severity of CAD and predicting patient outcomes. The study focuses on assessing the added value of CTCA to current methods in determining disease burden and cardiovascular risk. It is an observational retrospective study analyzing data collected from patients evaluated with CTCA over the past several years. Patients included in the study had CTCA performed using at least 64-slice CT technology or 16-slice with more than 4 years follow-up and had a calcium score available. The study collects data retrospectively from institutional databases, including clinical history, CTCA results, and follow-up records. Patients were classified based on CTCA findings into groups with normal arteries, non-obstructive CAD, or obstructive CAD. Data include detailed CT scanning protocols and administration of medications like beta-blockers and nitroglycerine during imaging. Participants information, such as cardiovascular risk factors and symptoms, was collected from clinical databases and interviews. Outcomes tracked include major adverse cardiovascular events MACE, coronary revascularizations, and shifts in cardiovascular risk categories. Follow-up data were obtained through outpatient visits, phone contacts, and medical records review, with a minimum follow-up of 6 to 12 months. Researchers analyze outcomes using various statistical methods to identify predictors of risk and the incremental value of CTCA in prognosis.